Muhammad Tahir Aleem | Health Sciences | Best Researcher Award

Dr. Muhammad Tahir Aleem | Health Sciences | Best Researcher Award 

Shantou University Medical College | China

Dr. Muhammad Tahir Aleem is a highly accomplished early-career scientist in the field of Preventive Veterinary Medicine and Molecular Parasitology, with a multidisciplinary research background spanning veterinary sciences, immunology, molecular biology, vaccine development, and zoonotic diseases. He holds a Doctor of Veterinary Medicine (DVM) and an M.Phil. in Parasitology from the University of Agriculture, Faisalabad, Pakistan, and earned his Ph.D. from Nanjing Agricultural University, China, where his doctoral research focused on the role of progesterone receptors in the reproduction of Trichinella spiralis, a key area in parasite biology. He completed two postdoctoral fellowships: one in Molecular Parasitology and Chromosome Biology at Cleveland State University, USA, and another in Basic Medicine at Shantou University Medical College, China. Dr. Aleem has authored over 15 peer-reviewed articles, including several in Q1 journals such as Vaccines, International Immunopharmacology, and Biomedical Research International, contributing to a cumulative impact factor exceeding 148.14. His studies delve into advanced vaccine design (mRNA, DNA), host-parasite interactions, immunomodulation, and molecular docking techniques, reflecting a strong command of both theoretical and applied biomedical sciences. He has served as corresponding author on multiple publications, highlighting his leadership in collaborative research. His work has garnered over 400 citations, with an estimated h-index of 8–10, showcasing his growing impact in the international scientific community. Dr. Aleem’s research has far-reaching implications for both veterinary and human health, especially in the control of parasitic diseases, emerging zoonoses, and infectious disease prevention. He actively collaborates across institutions and countries, demonstrating a global outlook and commitment to scientific innovation. His contributions to membrane-associated progesterone receptor studies have opened new avenues for reproductive parasitology, while his recent work on mRNA and DNA vaccine platforms marks him as a forward-looking investigator. He also contributes to public health and translational medicine by addressing environmental pathogens and drug development challenges. Given his high-impact publications, international collaborations, cross-disciplinary research profile, and growing citation footprint, Dr. Muhammad Tahir Aleem stands out as a promising and deserving candidate for the Best Researcher Award. His work not only advances veterinary and biomedical sciences but also paves the way for translational solutions to global health challenges.

Profiles: Scopus | Google Scholar

Featured Publications

COVIDSurg Collaborative, & GlobalSurg Collaborative. (2021). Timing of surgery following SARS‐CoV‐2 infection: An international prospective cohort study. Anaesthesia, 76(6), 748–758.

Sohail, M. U., Ijaz, A., Yousaf, M. S., Ashraf, K., Zaneb, H., Aleem, M., & Rehman, H. (2010). Alleviation of cyclic heat stress in broilers by dietary supplementation of mannan-oligosaccharide and Lactobacillus-based probiotic: Dynamics of cortisol, thyroid hormones and growth performance. Poultry Science, 89(9), 1934–1938.

Suleria, H. A. R., Butt, M. S., Khalid, N., Sultan, S., Raza, A., Aleem, M., & Abbas, M. (2015). Garlic (Allium sativum): Diet based therapy of 21st century – A review. Asian Pacific Journal of Tropical Disease, 5(4), 271–278.

Ijaz, A., Hussain, A., Aleem, M., Yousaf, M. S., & Rehman, H. (2009). Butylated hydroxytoluene inclusion in semen extender improves the post-thawed semen quality of Nili-Ravi buffalo (Bubalus bubalis). Theriogenology, 71(8), 1326–1329.

Sultan, S., Huma, N., Butt, M. S., Aleem, M., & Abbas, M. (2018). Therapeutic potential of dairy bioactive peptides: A contemporary perspective. Critical Reviews in Food Science and Nutrition, 58(1), 105–115.

Jamil, M., Aleem, M. T., Shaukat, A., Khan, A., Mohsin, M., Rehman, T. U., Abbas, R. Z., Saleemi, M. K., Khatoon, A., Babar, W., Yan, R., & Li, K. (2022). Medicinal plants as an alternative to control poultry parasitic diseases. Life, 12(3), 449.

Adeel, M., Ijaz, A., Aleem, M., Rehman, H., Yousaf, M. S., & Jabbar, M. A. (2009). Improvement of liquid and frozen-thawed semen quality of Nili-Ravi buffalo bulls (Bubalus bubalis) through supplementation of fat. Theriogenology, 71(8), 1220–1225.

COVIDSurg Collaborative, GlobalSurg Collaborative, Nepogodiev, D., et al. (2022). SARS‐CoV‐2 infection and venous thromboembolism after surgery: An international prospective cohort study. Anaesthesia, 77(1), 28–39.

Bajwa, H. U. R., Khan, M. K., Abbas, Z., Riaz, R., Rehman, T., Abbas, R. Z., Aleem, M. T., et al. (2022). Nanoparticles: Synthesis and their role as potential drug candidates for the treatment of parasitic diseases. Life, 12(5), 750.

Farooq, M., Durrani, F. R., Aleem, M., Chand, N., & Muqarrab, A. K. (2001). Egg traits and hatching performance of Desi, Fayumi and Rhode Island Red chicken. Pakistan Journal of Biological Sciences, 4(7), 909–911.

 

Jitendra Patil | Health Sciences | Best Researcher Award

Mr. Jitendra Patil | Health Sciences | Best Researcher Award

Mr. Jitendra Patil | Sankalchand Patel University Visnagar,Badoda | India

Mr. Jitendra Hilal Patil, Lecturer at H.R. Patel Institute of Pharmaceutical Education and Research, Shirpur, is a PCI-registered academic with a strong background in pharmaceutical sciences and nanotechnology. He holds an M.Pharm in Quality Assurance and is pursuing his Ph.D. at Sankalchand Patel University, Visnagar. His research focuses on developing pH-responsive nanocarrier drug delivery systems for targeted cancer therapy, with publications in Scopus-indexed journals and one patent under process. With a citation index of 29, his innovative work contributes significantly to advancing precision medicine while minimizing systemic toxicity in anticancer treatments.

Author Profile 

Scopus

Education

From the very beginning of his educational journey, Mr. Jitendra Hilal Patil demonstrated a keen interest in pharmaceutical sciences and biomedical research. His strong academic foundation was built through consistent excellence across secondary and higher secondary education, which he pursued with dedication and discipline. His pursuit of a Bachelor’s and Master’s degree in Pharmacy further sharpened his knowledge in drug formulation, quality assurance, and advanced pharmaceutical principles. These formative academic years not only shaped his scientific mindset but also ignited his passion for research in nanotechnology and innovative drug delivery systems. His pursuit of a Ph.D. reflects his commitment to expanding the boundaries of knowledge and contributing to global healthcare challenges.

Experience

Mr. Patil serves as a Lecturer at H.R. Patel Institute of Pharmaceutical Education and Research, Shirpur, where he plays a pivotal role in nurturing future pharmacists and researchers. His teaching approach integrates theory with practical insights, encouraging students to think critically about real-world healthcare challenges. Alongside his teaching responsibilities, he actively engages in research, ensuring his academic contributions are aligned with the latest developments in pharmaceutical innovation. His ability to balance teaching, research, and mentoring highlights his versatility as both an educator and a researcher. He also ensures his students are exposed to cutting-edge topics such as nanotechnology, targeted therapies, and drug delivery systems, preparing them to excel in the evolving landscape of pharmaceutical sciences.

Research Focus

The hallmark of Mr. Patil’s academic journey lies in his research on pH-responsive nanocarrier drug delivery systems designed for targeted cancer treatment. Recognizing the limitations of conventional chemotherapy—such as poor survival rates, systemic toxicity, and severe side effects—he focused on developing titanium-based metal-organic frameworks (Ti-MOFs) as nanocarriers for the anticancer drug axitinib (AXT).

Through advanced hydrothermal synthesis and characterization techniques, he successfully developed stable, porous nanostructures that exhibit excellent pH-responsive behavior. His in vitro studies revealed that these carriers released minimal drug amounts in neutral pH, simulating healthy tissues, but significantly increased release in acidic environments mimicking cancer cells. This innovation represents a major step toward precision medicine, offering the potential to reduce toxicity and enhance therapeutic efficacy. His work exemplifies how nanotechnology can transform oncology treatments, opening doors to more effective and patient-friendly therapies.

Awards and Recognition

Mr. Patil’s research has garnered recognition through Scopus-indexed publications, citations, and a patent under process, highlighting the originality and applicability of his work. With a citation index of 29, his publications demonstrate a meaningful academic impact and a growing influence in the pharmaceutical research community. He is also a registered member of the Pharmacy Council of India (PCI), further strengthening his professional credibility. While he has not yet accumulated multiple industry consultancy projects or editorial appointments, his promising work and contributions reflect the qualities of a rising researcher who is set to achieve even greater recognition at both national and international levels.

Impact and Influence

The potential impact of Mr. Patil’s research extends beyond academia, offering transformative possibilities in cancer treatment. By addressing the challenges of drug toxicity and inefficient targeting, his nanocarrier-based system has the potential to improve the quality of life for patients undergoing therapy. Moreover, his contributions set a strong foundation for future collaborations in nanomedicine, oncology research, and pharmaceutical technology. His influence also extends to his students, who benefit from his mentorship, guidance, and emphasis on research-driven learning. By bridging the gap between classroom knowledge and practical innovation, he inspires a new generation of pharmaceutical professionals to pursue impactful research that addresses pressing healthcare challenges.

Publications

Nonlocal thermoelastic diffusion analysis in a semi-infinite body subjected to thermal loading with memory effects.

Author: Jitendra Patil, Chandrakant Jadhav, Nitin Chandel & Vinod Varghese
Journal: Archive of Applied Mechanics
Year: 2025

Development and Characterization of AXT@Metal-Organic Framework: A Biocompatible, pH-Responsive Nanocarrier for Targeted Axitinib Delivery in MCF-7 Cancer Cells.

Author: Jayvadan K. Patel, Ujashkumar A. Shah, Pravin O. Patil, Jitendra H. Patil
Journal: Annales Pharmaceutiques Françaises
Year: 2025

Conclusion

Mr. Jitendra Hilal Patil exemplifies the qualities of a dedicated educator, an emerging researcher, and an innovator in pharmaceutical sciences. His academic journey, professional commitments, and research on pH-responsive nanocarriers reflect not only his scientific expertise but also his vision for improving global healthcare outcomes. With a growing body of impactful publications, a patent under process, and recognition as a promising voice in nanotechnology and drug delivery research, he continues to inspire both peers and students alike. Looking forward, his unwavering dedication positions him to make enduring contributions that bridge cutting-edge research with tangible benefits for society, leaving a meaningful legacy in academia and beyond.

Guoying Yu | Environmental Health | Best Researcher Award | 13389

Prof. Guoying Yu | Environmental Health | Best Researcher Award 

Prof. Guoying Yu, Henan Normal University, China

Professor Guoying Yu is a distinguished biomedical scientist and professor at the College of Life Sciences, Henan Normal University, China. With a Ph.D. in Ecology from the Chinese Academy of Sciences and postdoctoral experience at Yale and the University of Pittsburgh, Dr. Yu has made significant contributions to lung biology, focusing on acute lung injury, pulmonary fibrosis, and thyroid hormone-based therapies. His innovative research has been published in top-tier journals like Nature Communications and Advanced Science, and he has secured major national and provincial research grants. A leader in translational medicine, Dr. Yu is widely respected for his impactful work, international collaborations, and dedication to advancing global health through scientific innovation.

Profile

Scopus

🏫 Early Academic Pursuits

Professor Guoying Yu’s journey into science began with a deep-rooted passion for biology and ecology. Born in China, he pursued his undergraduate studies at Henan Normal University, graduating in 1985 with a strong academic foundation in life sciences. Determined to explore ecological systems at a deeper level, he obtained his Master’s degree from Yunnan University in 1989. His unwavering commitment to academic excellence propelled him toward doctoral studies, and he earned his Ph.D. in Ecology in 1995 from the Chinese Academy of Sciences, China’s leading research institution.

Dr. Yu’s Ph.D. work laid a critical foundation in interdisciplinary environmental biology, a focus that later expanded into biomedical research. His academic brilliance and research discipline were evident from these formative years, building a strong base for his future endeavors.

👨‍🔬 Professional Endeavors

After receiving his Ph.D., Dr. Yu broadened his horizons through prestigious postdoctoral fellowships at the University of Pittsburgh (USA) and the Chinese Academy of Sciences. His research during this period focused on biomedical applications of molecular ecology, marking his transition into translational and clinical research.

Over the years, he has held esteemed research and academic positions at globally recognized institutions including Yale University, University of Pittsburgh, and Chinese academic universities. Currently, Dr. Yu is a Professor at the College of Life Sciences at Henan Normal University, where he leads critical research in lung injury, pulmonary fibrosis, and drug development.

His career is characterized by a fusion of academic rigor and innovation, with a particular focus on diseases that have significant public health impacts.

🔬 Contributions and Research Focus

Professor Yu’s research spans molecular biology, immunology, pulmonary disease, and translational medicine. A notable area of focus has been his exploration of thyroid hormone analogs, especially GC-1, for the treatment of acute lung injury and pulmonary fibrosis. His findings have significantly contributed to the non-steroidal therapeutic approach to lung repair.

Some of his groundbreaking work includes:

  • The TRβ/KLF2/CEBPA axis, which enhances alveolar repair by guiding alveolar type 2 to type 1 cell differentiation.

  • The inhibition of macrophage inflammasomes to control cytokine storms and lung injury.

  • The identification of MMP19 from endothelial cells as a critical contributor to pulmonary fibrosis.

His work integrates molecular mechanisms with clinical application and has been published in top-tier journals such as Nature Communications, Advanced Science, Theranostics, and Cell Communication and Signaling.

🏅 Accolades and Recognition

Dr. Yu’s research excellence has earned him national and provincial funding awards from:

  • National Key Research and Development Program (2020–2023) – ¥2.85 million

  • Zhongyuan Foreign Expert Program (2020–2021) – ¥220,000

  • Henan Major Scientific and Technological Projects (2024–2026) – ¥2 million

He is recognized as a leading talent in Henan Province, and has been entrusted with managing high-impact biomedical research projects. His leadership roles in academic and governmental collaborations underscore his credibility as a national research leader.

🌍 Impact and Influence

Dr. Yu’s influence transcends borders. His international collaborations, particularly with institutions in the United States such as Yale and Pittsburgh, have facilitated the global exchange of knowledge. His work on post-COVID-19 lung pathology, innovative drug discovery, and inflammation control strategies have directly impacted public health strategies and pharmaceutical development in China.

With over 1,300 citations and increasing global interest in his work, Dr. Yu is regarded as an authority in pulmonary disease mechanisms, especially within the translational research community.

🌱 Legacy and Future Contributions

Professor Guoying Yu’s legacy lies in his ability to bridge scientific innovation with practical application. As a mentor, he continues to shape the next generation of scientists at Henan Normal University. As a scientific leader, his vision for the future includes:

  • Developing affordable therapies for lung diseases in low- and middle-income countries.

  • Enhancing China’s biomedical innovation pipeline through international cooperation.

  • Advancing precision medicine approaches tailored to complex respiratory conditions.

His ongoing work positions him not only as a trailblazer in translational lung biology but also as a guiding force for future biomedical innovation in Asia and beyond.

Publication Top Notes

Author: Z., Li, Zhongzheng, M., Zhang, Mengke, Y., Zhang, Yujie, G., Yu, Guoying, L., Wang, Lan

Journal: Epigenetics and Chromatin

Year: 2025

Author: H., Lian, Hui, Y., Zhang, Yujie, Z., Zhu, Zhao, L., Wang, Lan, G., Yu, Guoying

Journal: Life Science Alliance

Year: 2025

Author: X., Pan, Xin, L., Wang, Lan, J., Yang, Juntang, I.O., Rosas, Ivan O., G., Yu, Guoying

Journal: Nature Communications

Year: 2024